Payment overview · 2025
General Payments
$771.41
22 reported records · 10 companies
Healthcare provider profile · identity verified
Harrell A Grand, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1982623252
Verified facts
What the public records show
CMS Open Payments records show Harrell A Grand, MD received $771.41 in general payments during 2025 across 22 reported records.
Madrigal Pharmaceuticals accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $174.18 | 22.6% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $135.87 | 17.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.17 | 14.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.09 | 13.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.76 | 8.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.46 | 7.1% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $52.31 | 6.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.01 | 3.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.29 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.27 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $771.41 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $174.18 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $109.17 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $102.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $90.17 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $90.17 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $90.17 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.23 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 336 | 96 |
| Alprazolam | Alprazolam | 131 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 116 | 39 |
| Trazodone Hcl | Trazodone Hcl | 104 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 82 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 81 | 29 |
| Omeprazole | Omeprazole | 75 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 12 |
| Metformin Hcl Er | Metformin Hcl | 63 | 20 |
| Synthroid | Levothyroxine Sodium | 63 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 18 |
| Montelukast Sodium | Montelukast Sodium | 53 | 18 |
| Valsartan | Valsartan | 50 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 17 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Dovato | Dolutegravir Sodium/Lamivudine | 45 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 13 |
| Carvedilol | Carvedilol | 41 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Furosemide | Furosemide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Gabapentin | Gabapentin | 34 | 16 |
| Lisinopril | Lisinopril | 34 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Metformin Hcl | Metformin Hcl | 33 | 11 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Losartan Potassium | Losartan Potassium | 31 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 13 |
| Eliquis | Apixaban | 25 | 11 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $771.41 · 22 records | Madrigal Pharmaceuticals | ABRYSVO, AIRSUPRA, APRETUDE, Auvelity, COMIRNATY, DOVATO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REZDIFFRA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error